Aldeyra Therapeutics Inc (NASDAQ:ALDX) rallied to a new all-time high Thursday after Aegis Capital began coverage of the biotech company working to develop treatments for rare skin and eye diseases with a Buy rating. Aldeyra Therapeutics Inc (NASDAQ:ALDX) stock performance was 12.26% in last session and finished the day at $7.51. Traded volume was 134,905.00million shares in the last session and the average volume of the stock remained 26.32K shares. Aldeyra Therapeutics Inc (NASDAQ:ALDX) insider ownership is 1.20%.
Alcobra Ltd. (NASDAQ:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the JMP Securities Healthcare Conference, taking place June 24-25 in New York City. Alcobra Ltd (NASDAQ:ADHD) dropped -0.47 percent to $18.70 Thursday on volume of 427,396.00million shares. The intra-day range of the stock was $18.32 to $19.50. Alcobra Ltd (NASDAQ:ADHD) has a market capitalization of $255.01million.
Receptos Inc (NASDAQ:RCPT) has announced offering of about 4.43 million common stock shares with the possibility of selling additional 664,950 shares if the demand is high. The underwritten shares are being offered at $40.25 per share to the public, and the offering will close next week on June 24. Receptos Inc (NASDAQ:RCPT)’s stock on June 19, 2014 reported a decrease of -2.76% to the closing price of $39.86. Its fifty two weeks range is $15.21 -$55.00. The total market capitalization recorded $883.67million. The overall volume in the last trading session was 2.17million shares. In its share capital, RCPT has 22.17million outstanding shares.
Celsus Therapeutics Plc (ADR) (NASDAQ:CLTX), an emerging growth, development-stage biotech company, has received approval from the Israeli Ministry of Health to conduct a Phase II trial of MRX-6 cream 2% in pediatric patients with atopic dermatitis. On Thursday, shares of Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) dropped -2.30% to close the day at $6.80. Company monthly performance is recorded as 30.77%. Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX) quarterly revenue growth is -1.45%.